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Haydar A. Frangoul1Total body irradiation (TBI)-based conditioning regimens for pediatric patients with acute myelogenous leu-
kemia (AML) beyond first complete remission (CR1) are controversial. Because the long-term morbidity of
busulfan (Bu)-based regimens appears to be lower, determining efficacy is critical. We retrospectively eval-
uated 151 pediatric patients with AML beyond CR1, comparing outcomes in 90 patients who received a TBI-
based conditioning regimen and 61 patients who received a Bu-based conditioning regimen. There were no
differences between the 2 groups with respect to age, sex, duration of CR1, time frommost recent remission
to transplantation, or donor source. The probability of relapse at 2 years also did not differ between the 2
groups (26% and 27%, respectively; P5.93). No significant difference in event-free survival (EFS) (P5.29) or
overall survival (OS) (P5.11) was noted between the 2 groups. These findings were supported by a multivar-
iate analysis in which TBI was not associated with improved EFS (hazard ratio [HR]51.17; 95% confidence
interval [CI]50.66-2.10; P5.58) or OS (HR51.42; 95% CI50.76-2.64; P5.27). Shorter CR1 and receiving an
HLA-mismatched transplant adversely affected EFS andOS in this cohort. Our study provides no evidence of
an advantage to using TBI in children with AML beyond CR1. A prospective, randomized study is needed to
confirm these results.
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Whereas 80%-90% of children with acute mye-
logenous leukemia (AML) achieve complete remission
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6/j.bbmt.2009.08.014remains only 40%-50% [1]. Nearly half of those who
achieve CR will eventually relapse. For these patients,
hematopoietic stem cell transplantation (HSCT) often
is the only curative option [1,2]. Conditioning regi-
mens including total body irradiation (TBI) in combi-
nation with high dose chemotherapy have been used in
patients with AML since the 1970s, and such regimens
are known to be effective in achieving engraftment and
eradicating disease [3]. Unfortunately, however, TBI-
based regimens have significant late effects in children,
including growth impairment, cataracts, endocrinopa-
thies, cognitive delay, and increased incidence of sec-
ondary malignancies specifically associated with
exposure to irradiation [4-6].
Busulfan (Bu)-containing regimens offer an alter-
native to TBI-based regimens and have been consid-
ered the standard conditioning regimen in North
America for young patients with AML in first CR
(CR1) [3,7]. The role of Bu-based regimens in patients
beyond CR1 remains controversial, however. Overall,
Bu-based regimens have less expected long-term
Biol Blood Marrow Transplant 15:1620-1627, 2009 1621Conditioning Regimen in Pediatric AML beyond First Complete Remssionmorbidity in children, including lower rates of growth
impairment, cataracts, cognitive delay, and certain ma-
lignancies associated with exposure to irradiation [6,8].
Other side effects, including thyroid dysfunction, seem
to be similar in those receiving Bu-containing and
TBI-containing regimens. One advantage is of the for-
mer is that Bu is easier to administer to young children,
who often require sedation or anesthesia for TBI [9].
Although patients who receive Bu are more likely to
develop veno-occlusive disease (VOD) of the liver
and permanent alopecia [9,10], such side effects have
become less common with the routine use of i.v. Bu
and the advent of pharmacokinetic studies to ensure
proper dosing in pediatric patients [11,12].
In an effort to define the most effective regimen for
children undergoing allogeneic HSCT with AML be-
yond CR1, we compared treatment-related mortality
(TRM), relapse, and survival in a cohort of pediatric pa-
tients who received a TBI-based or a Bu-based condi-
tioning regimen.MATERIALS AND METHODS
We retrospectively reviewed data for pediatric
patients with AML who underwent allogeneic HSCT
between 2000 and 2008 using data provided by the
Pediatric Blood and Marrow Transplant Consortium
(PBMTC). The PBMTC collects data on demo-
graphic, disease, and transplantation characteristics,
as well as outcome data on related and unrelated donor
transplantations from 61 institutions in the United
States, Canada, Australia, and New Zealand. Data
were collected for each patient at the time of transplan-
tation andonday1100 and1 year after transplantation.
Consent was obtained prospectively, and data were
submitted using a unique identifying number. The
data were stripped of identifying information before
being provided to the authors for analysis. The design
of this study was approved by Vanderbilt University
Medical Center’s Institutional Review Board.
Our initial query of the PBMTC database identi-
fied 193 patients with AML beyond CR1 who under-
went allogeneic HSCT at 59 study centers. Centers
were asked to provide extended longitudinal follow-
up data through their existing data use agreements
with the PBMTC. A total of 48 centers (81%) chose
to participate and provided data for consecutively
treated patients at their center. A total of 184 (95%)
of the identified patients in the PBMTC registry
were included in this study.
Patients aged #21 years with AML who under-
went fully myeloablative (MA) HSCT beyond CR1
or with refractory disease with a graft from a related
or an unrelated donor are included in the study. Pa-
tients who had secondary AML, had a previous trans-
plantation, or who received conditioning regimens
that were not either TBI-based or Bu-based wereexcluded. This analysis includes patients who received
a bone marrow (BM), cord blood (CB), or peripheral
blood stem cell (PBSC) transplant. A total of 151 pa-
tients met the inclusion criteria and were included. Pa-
tients were stratified based on the conditioning
regimen received before HSCT, either a TBI-contain-
ing or a Bu-containing regimen.Ninety patients (60%)
received a TBI-based conditioning regimen, and 61
patients (40%) received a Bu-based conditioning regi-
men.
In both groups, patients most commonly received
TBI or Bu in combination with cyclophosphamide
(Cy). In the TBI group, 86 patients (96%) received
TBI with cyclophosphamide, 1 patient received TBI
with melphalan, and 3 patients received TBI with flu-
darabine (Flu). Thirty-five patients (57%) in the Bu
group received Bu with Cy, 19 (31%) received Bu
with melphalan (Mel), and 7 (12%) received Bu with
fludarabine (Flu). A comparison of event-free survival
(EFS) and overall survival (OS) in the patients receiv-
ing different Bu-containing regimens revealed no dif-
ferences; thus, for this analysis, all patients who
received Bu-based regimens are considered a single
group. Centers also reported the route of Bu adminis-
tration (i.v. or oral) and whether or not busulfan dosing
was adjusted based on pharmacokinetics.
AML subtypes were classified using the French-
American-British system. Risk stratification because
of cytogenetic abnormalities was classified according
to the most recent Children’s Oncology Group crite-
ria. Cytogenetics were considered favorable if t(8;21)
or t(15;17) or inversion 16 was present; unfavorable
if -5, -7 or del (5q) was present; and standard risk for
normal karyotype, complex cytogenetics, and all
others. Pretransplantation performance score was as-
signed by the transplant centers and was considered
good if the Lansky/Karnofsky score was $80 and
poor if the Lansky/Karnofsky score was\80.
The primary outcomes studied were acute and
chronic graft-versus-host disease (aGVHD, cGVHD),
relapse,TRM,EFS, andOS.The incidence of grade II-
IV aGVHD and limited or extensive cGVHD in all
patients was determined. Grading was based on previ-
ously reported criteria [13]. Any death occurring dur-
ing continuous remission was defined as TRM.
Relapse was defined as recurrence of leukemia at any
site, andEFSwas defined as survival in a state of contin-
uousCR.Wehypothesized that theBu- andTBI-based
regimens would have similar EFS and OS.
Statistical Analysis
Univariate analyses were conducted usingWilcox-
on’s rank-sum test for continuous variables and
Fisher’s exact test for categorical (including dichoto-
mous) variables. Median values with ranges are
reported for continuous variables. Time-to-event
data are displayed using the Kaplan-Meier method,
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ducted using log-rank tests. Cox regression analysis
was used to model hazard ratios and the covariates of
interest. Proportionality assumptions were assessed
graphically by plotting Schoenfeld residuals [14] for
each explanatory variable and also by checking the cor-
relation coefficients between them. Time to relapse
was analyzed in competing-risks survival models to ac-
count for death without relapse. All statistical analyses
were conducted using R 2.7.0 [15], and a 2-sided sig-
nificance level of .05 was used for statistical inference.RESULTS
Patient Characteristics
Patient, disease, and transplant characteristics are
summarized inTable 1.Themedian age at transplanta-
tion was 9 years (range,\ 1-21 years). Most patients
(92%) were in second CR (CR2) at the time of trans-
plantation; 4% were in CR3 or CR4, and 4% were
not in remission. A majority of the patients (82%) had
intermediate-risk cytogenetics, 14%had low-risk cyto-
genetics, and 3% had high-risk cytogenetics. Eighty-
three percent of the patients received an unrelated
donor transplant. Forty-one percent of the patients
received BM, 39% received CB, and 19% received
PBSCs. No patient received a T cell–depleted graft
or other anti–T cell antibody therapy. The most com-
mon GVHD prophylactic regimens were cyclosporine
(CsA) or tacrolimus in combination with methotrexate
and did not differ between the 2 groups. The median
follow-up time was 2.7 years (range, 0.25-8 years).
The 2 groups were similar in terms of age, sex, cy-
tomegalovirus positivity, duration of CR1, and disease
status at the time of transplantation. Significantlymore
patients in the TBI group had a history of extramedul-
lary disease (EMD) (P5.02). The most common site of
EMD was the central nervous system (CNS) in both
groups. The proportion of patients with a poor perfor-
mance score was higher in the Bu-based conditioning
group (10% vs 2%), but the difference was not statisti-
cally significant. The 2 groups were otherwise similar
for all other factors analyzed.
A majority of the patients (74%) received i.v. Bu,
and 26% received oral Bu.Wewere not able to identify
individual patients who had a Bu dosing adjustment
based on pharmacokinetic studies; however, the pro-
portion of the study centers that routinely used tar-
geted Bu dosing grew from 51% at the beginning of
the study period to 93% by the end of the study period.Univariate Analysis
Univariate comparisons of transplantation out-
comes between the 2 groups are presented in Table 2.
The median time to neutrophil engraftment (definedas first day of achieving an absolute neutrophil count
.500/mL) did not differ between the 2 groups: 17
days in the Bu group and 19 days in the TBI group
(P5.14). Graft failure was an uncommon event, with
1 patient in each group failing to engraft.
Overall, 44% of patients developed grade II-IV
aGVHD, but only 19% had severe disease (grade III-
IV). Among the patients alive for evaluation after day
1100, the incidence of limited and extensive cGVHD
was 11% and 15%, respectively. There was no differ-
ence in the incidence of aGVHD (P5.74) or cGVHD
(P5.75) between the patients who received TBI and
those who received Bu.
Overall probability ofTRMat4yearswas26%(95%
confidence interval [CI]519%-37%) (Figure 1A). The
most common cause of TRM in both groups was
GVHD(n515), followedby infection (n57) andpulmo-
nary toxicity (n56). The probability of TRM at 4 years
was not statistically different between the 2 groups (Bu
group: 20%, 95% CI57%-30%; TBI group: 32%,
95% CI517%-43%; P5.74).
Theprobabilityof relapse at4yearswas slightly lower
in the TBI group, but the difference was not statistically
significant (TBI group: 24%, 95% CI515%-34%; Bu
group: 31%, 95% CI517%-45%) (Figure 1B). The
EFS at 4 years for all patients was 46% (95% CI537%-
55%), and it was not significantly different between the
TBI and Bu groups (45%, 95% CI535%-58% vs 49%,
95% CI536%-66%; P5.5) (Figure 1C).
The probability of OS at 4 years for all patients was
49% (95%CI540%-58%). The probability of OS at 4
years was lower in the TBI group, but the difference
was not statistically significant (45%, 95% CI535%-
58% vs 56%, 95% CI543%-72%; P5.2) (Figure 1D).
The causes of death are listed in Table 3.Multivariate Analysis
Table 4 lists the variables included in our Cox pro-
portional hazards regression model. This model sup-
ported the finding that the conditioning regimen did
not independently influence rates of OS, EFS, relapse,
or TRM when other risk factors were considered.
Longer duration of CR1 was associated with signifi-
cantly improved EFS (hazard ratio [HR]50.94; 95%
CI50.91-0.97; P5.001) and OS (HR50.93; 95%
CI50.90-0.97; P\ .001). Patients with a HLA-mis-
matched donor had significantly higher rate of TRM
(HR53.07; 95% CI51.08-8.73; P5.04) and worse
EFS (HR52.04; 95% CI51.10-3.77; P5.024) and
OS (HR52.04; 95%CI51.07-3.86; P5.03). Similarly,
a longer time from achievement of CR2/3 to trans-
plantation was significantly associated with higher
TRM (HR51.43; 95% CI51.10-1.85; P5.008) and
worse EFS (HR51.21; 95% CI51.02-1.44; P5.03)
and OS (HR51.28; 95% CI51.07-1.53; P5.007). Al-
though patients with a history of EMD were almost
Table 1. Patient, Disease and Transplant Characteristics
N Bu Group (n561) TBI Group (n590) Combined (n5151) P
Age, years, median (range) 151 7.9 (0.8-21.6) 10.9 (0.8-19.5) 9.2 (0.8-21.6) .26
Male sex 151 59% (36) 49% (44) 53% (80) .24
Disease status 151 .26
CR2 97% (59) 89% (80) 92% (139)
CR3+ 2% (1) 6% (5) 4% (6)
Refractory disease 2% (1) 6% (5) 4% (6)
Performance score 142 .07
Good 90% (53) 98% (81) 94% (134)
EMD 150 18% (11) 36% (32) 29% (43) .02
Site 1.0
CNS 64% (7) 59% (19) 60% (26)
Chloroma 18% (2) 19% (6) 19% (8)
Skin 18% (2) 16% (5) 16% (7)
Testicular 0% (0) 6% (2) 5% (2)
Cytogenetics 119 .67
Favorable risk 11% (6) 17% (11) 14% (17)
Intermediate risk 85% (45) 80% (53) 82% (98)
Unfavorable risk 4% (2) 3% (2) 3% (4)
Disease subtype 151 .18
M0 7% (4) 8% (7) 7% (11)
M1 15% (9) 11% (10) 13% (19)
M2 13% (8) 24% (22) 20% (30)
M3 11% (7) 3% (3) 7% (10)
M4 25% (15) 16% (14) 19% (29)
M5 13% (8) 19% (17) 17% (25)
M6 0% (0) 0% (0) 0% (0)
M7 7% (4) 4% (4) 5% (8)
AML unspecified 10% (6) 14% (13) 13% (19)
Duration of CR1, months(range) 135 9.5(1-48) 12.0(1-60) 12.0(1-60) .14
Time from CR 2/3 to transplantation, months
(range)
142 1.13(0.23-6) 2.0(0.27-10.4) 1.5(0.23-10.4) .09
Donor type 151 .13
Related 23% (14) 13% (12) 17% (26)
Cell source 150 .41
Bone marrow 35% (21) 46% (41) 41% (62)
Cord blood 45% (27) 36% (32) 39% (59)
PBSCs 20% (12) 19% (17) 19% (29)
Donor–recipient sex 142 .76
Female–female 20% (11) 23% (20) 22% (31)
Male–male 29% (16) 29% (25) 29% (41)
Female–male 29% (16) 21% (18) 24% (34)
Male–female 23% (13) 27% (23) 25% (36)
Recipient cytomegalovirus status 146 .09
Positive 46% (28) 61% (52) 55% (80)
HLA matching 145
Bone marrow 60 > .99
Fully matched 71% (15) 72% (28) 72% (43)
Mismatched 29% (6) 28% (11) 28% (17)
Cord blood 58 > .99
Fully matched 8% (2) 9% (3) 9% (5)
Mismatched 92% (24) 91% (29) 91% (53)
PBSCs 27 > .99
Fully matched 67% (8) 73% (11) 70% (19)
Mismatched 33% (4) 27% (4) 30% (8)
GVHD prophylaxis 148 .12
CsA/FK alone 2% (1) 9% (8) 6% (9)
CsA/FK + MTX 36% (22) 43% (37) 40% (59)
CsA/FK + MMF 18% (11) 9% (8) 13% (19)
CsA/FK + steroids 25% (15) 16% (14) 20% (29)
Other 20% (12) 23% (20) 22% (32)
CsA indicates cyclosporine; FK, tacrolimus; PBSCs, peripheral blood stem cells; AML, acute myelogenous leukemia; CR, complete response; EMD, ex-
tramedullary disease; GVHD, graft-versus-host disease; MTX, methotrexate; MMF, mycophenolate.
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tically significant (P5.18).
There was a trend toward worse EFS (HR51.98;
95% CI50.99-3.96; P5.054) and OS (HR52.00;
95% CI50.98-4.06; P5.055) in patients with historyof EMD. Adding an interaction term for condition-
ing regimen and history of EMD yielded no evi-
dence that conditioning regimen had a different
effect on relapse, TRM, EFS, or OS in patients
with a history of EMD. Interestingly, known risk
Table 2. UnivariateAnalysis of TransplantationOutcomes of Patients ReceivingHSCTbeyondCR1byTransplantation Preparative
Regimen
n Bu Group (n561) TBI Group (n590) Combined (n5151) P
Days to engraftment 17 (15-21) 19 (17-21) .14
Acute GVHD (grade II-IV) 150 41% (25) 45% (40) 44% (65) .74
Severe acute GVHD (grade III/IV) 150 18% (11) 19% (17) 19% (28) .9
Chronic GVHD 143 .75
Limited 13% (8) 10% (8) 11% (16)
Extensive 13% (8) 16% (13) 15% (21)
Relapse 151 .740
At 2 years 27 (15%-39%) 24 (15%-34%) 25 (18%-33%)
At 4 years 31 (17%-45%) 24 (15%-34%) 27 (19%-35%)
At 6 years 31 (17%-45%) 24 (15%-34%) 27 (19%-35%)
TRM 151 .289
At 2 years 16 (6%-26%) 25 (14%-34%) 21 (15%-30%)
At 4 years 20 (7%-30%) 32 (17%-43%) 26 (19%-37%)
At 6 years 20 (7%-30%) 32 (17%-43%) 26 (19%-37%)
EFS 151 .293
At 2 years 63 (51%-77%) 49 (40%-61%) 55 (46%-63%)
At 4 years 49 (36%-66%) 45 (35%-58%) 46 (37%-55%)
At 6 years 37 (19%-70%) 45 (35%-58%) 41 (27%-53%)
OS 151 .117
At 2 years 66 (55%-80%) 49 (40%-61%) 56 (47%-64%)
At 4 years 56 (43%-72%) 45 (35%-58%) 49 (40%-58%)
At 6 years 56 (43%-72%) 45 (35%-58%) 49 (40%-58%)
HSCT indicates hematopoietic stem cell transplantation; CR, complete response; GVHD, graft-versus-host disease; TRM, treatment-related mortality;
EFS, event-free survivial.
Footnote: Data presented in parentheses for GVHD represent the % and number of patients affected. Data presented in parentheses for incidence of
relapse, TRM, EFS and OS represent a range for 95% CI.
1624 Biol Blood Marrow Transplant 15:1620-1627, 2009I. Y. Sisler et al.factors for relapse and survival, such as donor type
(related vs unrelated) and age, were not found to in-
dependently influence transplantation outcomes in
this multivariate analysis.Figure 1. TRM (A), incidence of relDISCUSSION
Despite significant improvements in the treatment
of AML in children, a high proportion of patientsapse (B), EFS (C), and OS (D).
Table 3. Causes of Death
Cause of Death Bu Group TBI Group Combined
Total deaths 23 45 68
Leukemia 9 23 32
Transplantation-related 14 22 36
Acute GVHD 3 6 9
Chronic GVHD 3 3 6
Infection 3 4 7
Pulmonary toxicity 3 3 6
Liver failure 0 1 1
VOD 0 1 1
PTLD 0 1 1
Other 2 3 5
GVHD indicates graft-versus-host disease; VOD, veno-occlusive dis-
ease; PTLD, post transplant lymphoproliferative disease.
Table 4. Variables Tested in a Cox Proportional Hazards
Regression Model for the Association with the Primary Out-
comes of Interest (OS, EFS, TRM, and Relapse)
HR 95% CI P
OS
Related donor 1.24 0.53-2.91 .63
History of EMD 2.00 0.98-4.06 .055
Female donor 0.78 0.44-1.40 .41
Age 0.99 0.95-1.04 .69
Time from last CR to transplantation 1.28 1.07-1.53 .007
Duration of CR1 0.93 0.90-0.97 < .001
HLA antigen ismatch 2.04 1.07-3.86 .03
TBI-based preparative regimen 1.42 0.77-2.65 .27
EFS
Related donor 1.71 0.81-3.64 .16
History of EMD 1.98 0.99-3.96 .054
Female donor 0.84 0.48-1.48 .550
Age 1.00 0.96-1.05 .95
Time from last CR to transplantation 1.21 1.02-1.44 .03
Duration of CR1 0.94 0.91-0.97 .001
HLA antigen mismatch 2.04 1.10-3.77 .02
TBI-based preparative regimen 1.18 0.66-2.11 .58
TRM
Related donor 1.44 0.41-5.04 .57
History of EMD 1.73 0.51-5.84 .38
Female donor 1.06 0.41-2.72 .91
Age 1.08 1.00-1.17 .04
Time from last CR to transplantation 1.43 1.10-1.85 .008
Duration of CR1 0.95 0.91-1.00 .06
HLA antigen mismatch 3.07 1.08-8.73 .03
TBI-based preparative regimen 0.85 0.32-2.23 .74
Relapse
Related donor 1.77 0.70-4.44 .23
History of EMD 1.93 0.74-5.05 .18
Female donor 0.68 0.34-1.35 .27
Age 0.95 0.89-1.01 .08
Time from last CR to transplantation 1.05 0.86-1.28 .63
Duration of CR1 0.94 0.88-1.00 .05
HLA antigen mismatch 1.31 0.57-2.99 .53
TBI-based preparative regimen 1.20 0.54-2.67 .66
HSCT indicates hematopoietic stem cell transplantation; CR, complete
response; GVHD, graft-versus-host disease; TRM, treatment-related
mortality; EFS, event-free survival; EMD, extramedullary disease; TBI,
total body irradiation.
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important opportunity for cure in this population.Cur-
rently, there are no data comparing conditioning regi-
mens in childrenwithAMLbeyondCR1, and only very
little data exist in adults. This study was undertaken to
explore whether Bu-based conditioning regimens or
TBI-based conditioning regimens represent a better
option for pediatric patients in this clinical scenario.
The data presented here indicate no difference in the
time to engraftment or in the incidence of GVHD,
OS, EFS, TRM, or relapse between the 2 groups.
These findings suggest that pediatric patients with
AML beyond CR1 might not require TBI as part of
their preparative regimen.
The largest series of pediatric patients undergoing
HSCT for AML beyond CR1 to date is a retrospective
analysis of data from theNationalMarrowDonor Pro-
gram (NMDP) by Bunin et al [16]. A large majority of
their patients received a TBI-based conditioning regi-
men (87%), which precluded those authors from mak-
ing any comparison based on conditioning regimen. In
that study, OS was 47%, comparable to the OS in the
present study.
Previously published reports in adults with ad-
vanced disease are difficult to interpret because they
often include acute and chronic myelohenous malig-
nancies in different stages of disease. Patients with
AML beyond CR1 represent a minority of patients an-
alyzed. One single-center trial prospectively enrolled
adult patients with high-risk AML, including patients
with refractory and relapsed disease [17]. Of the 45 pa-
tients enrolled in that study, 27 (60%) underwent
transplantation in CR2/3 (n511) or with refractory
disease (n516). The authors reported no difference
in OS or EFS between patients who received a Bu-
based regimen and historic controls who received
a TBI-based regimen. In their analysis, the only factors
associated with a poor outcome were active disease at
the time of transplantation and receipt of anHLA-mis-
matched transplant. The authors did not include a sep-
arate analysis of patients beyond CR1. To the best of
our knowledge, there is only one other prospectivestudy [18] and one retrospective analysis [19] in the lit-
erature comparing conditioning regimens in adult pa-
tients with advanced AML. Both of these analyses
included patients with other hematologic malignancies
besides patients with AML. The majority of AML pa-
tients in both reports were in CR1, with only a small
proportion having advanced disease. Neither study
demonstrated improved or decreased survival in pa-
tients who received a TBI-based conditioning regimen
[18,19].
The largest study comparing Bu and TBI in CR1 is
a retrospective review of 581 adults from the Interna-
tional Bone Marrow Transplant Registry [20]. The
patients in the Bu group had a significantly increased
risk of extramedullary relapse; however, there was no
difference between the 2 groups in terms of the inci-
dence of BM relapse, TRM, EFS, or OS. The in-
creased number of CNS relapses in the Bu group in
that study led the authors to conclude that TBI is supe-
rior in its ability to eradicate EMD [20].
1626 Biol Blood Marrow Transplant 15:1620-1627, 2009I. Y. Sisler et al.In our cohort, the TBI group had a greater number
of patients with a history of EMD.One potential expla-
nation for this is that practitioners preferred TBI for
patients with EMD in the belief that TBI is superior
to Bu in the setting of CNS disease. The assumption
that TBI is superior for EMD has never been formally
tested, and our results do not support that conclusion.
However, our study size lacked sufficient power to de-
tect amodest difference in relapse rates in patients with
EMD, and our results must be interpreted with cau-
tion. Given the long-term complications associated
with TBI-based regimens and the relative frequency
of AML EMD, a prospective study comparing regi-
mens appears to be both warranted and feasible.
When choosing a conditioning regimen, clinicians
must consider the early and long-term toxicity of their
use, in addition to their efficacy. Data on early toxicity
were not available for much of our cohort, and our du-
ration of follow-up was not sufficient to allow us to
compare the incidence of delayed toxicity in these 2
groups. But, historical data suggest that Bu carries
less risk of long-term toxicity in children, and that
the incidence of early toxicity is comparable in the 2
regimens. Proponents of TBI argue that its use avoids
many of the early toxicities that are unique to Bu,
namely an increased incidence of VOD of the liver
and, in some studies, interstitial pneumonia [9,10].
Many of the studies making such claims were done us-
ing standard doses of oral Bu without any pharmacoki-
netic monitoring [10]. Oral Bu dosing is associated
with interpatient variability in absorption and first-
pass hepatic metabolism, which is undesirable in
a drug with a narrow therapeutic window [11]. High
Bu exposure has been associated with increased inci-
dence of VOD, and low exposure has been linked to in-
creased risk of graft rejection and relapse [21].
Although using an i.v. formulation nearly eliminates
the interindividual variability in adults, some variabil-
ity still exists in children [11]. For this reason, many
centers use therapeutic drug monitoring. Targeted
i.v. Bu dosing has been associated with increased OS
and EFS compared with conventional i.v. Bu dosing
[21]. Although many patients in this study did receive
targeted i.v. Bu, some did not receive what would be
considered optimized Bu dosing. Optimal Bu dosing
could potentially decrease the incidence of early toxic-
ity and lead to fewer relapses. Data on the incidence of
nonfatal VODwas not available for our cohort, but it is
worth noting that the only patient in this study to die of
VOD received a TBI-based conditioning regimen.
Late sequelae related to the conditioning regimen
not only may affect the quality of life, but also may be
life-threatening. TBI and Bu are associated with mul-
tiple late complications, including endocrinopathies,
cataracts, interstitial pneumonitis, neurocognitive or
behavioral difficulties, and secondary malignancies.
Endocrinopathies include thyroid dysfunction, growthabnormalities, and abnormalities in ovarian function
and spermatogenesis [6]. A retrospective analysis of
112 children who underwent HSCT for hematologic
malignancies and survived to at least 1 year after trans-
plantation (mean follow-up, 8.9 years) found an associ-
ation between the use of TBI and an increased risk of
numerous late complications, including cataracts and
osteoarticular complications, such as avascular necro-
sis [4]. The only patients who developed cardiac com-
plications, such as hypertension or cerebrovascular
injuries, were those who had received TBI. In a univar-
iate analysis, receipt of TBI was the most important
factor in the development of hypothyroidism [4]. In
addition, very young patients (\ 4 years) have been
shown to have a less favorable neuropsychological out-
come when receiving TBI compared with chemother-
apy alone [8].
In conclusion, the present study found no signifi-
cant difference in OS, EFS, TRM, or incidence of
relapse in pediatric patients with AML beyond CR1
who received a Bu-based conditioning regimen and
those who received a TBI-based regimen. Limitations
of our study include its retrospective nature and het-
erogeneity in the preparative regimens within the Bu
and TBI groups. A prospective, randomized study us-
ing uniform conditioning regimens with targeted Bu
dosing is needed to confirm our results and to evaluate
the long-term side effects associated with each regi-
men in children.
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